MAY 16·TradingViewHigh
Compugen Ltd expected to post a loss of 7 cents a share - Earnings Preview
Compugen Ltd is expected to report a loss of 7 cents per share. This earnings preview provides a brief outlook on the company's financial performance.
StockHealthcare · Biotechnology
$CGEN
COMPUGEN LTD
Price · $CGENvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $CGEN in the last 7 days.
Insider · 30dFeed →
No SEC Form 4 filings for $CGEN in the last 30 days.
Top stories · $CGENMore →
APR 9·Stock Titan
Compugen management takes virtual Needham healthcare stage April 13
Compugen (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45–9:25 AM ET. A live webcast and replay will be available on the company’s investor relations website. This follows several positive corporate updates, including strong 2025 financial results, an extended cash runway, and a royalty monetization deal with AstraZeneca.
MAR 3·Seeking Alpha
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement (CGEN)
Compugen has secured non-dilutive funding from AstraZeneca for rilvegostomig royalties, bolstering its financial stability and extending its cash runway into 2029. The company, rated a 'Buy,' is advancing its pipeline with key catalysts including the phase 3 MAIA-Ovarian cancer trial for COM701 and the phase 1 anti-IL18BP antibody GS-0321. Potential milestone payments of up to $1 billion from AstraZeneca and Gilead, along with mid-single-digit royalties, offer significant future upside.